A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease.
A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease.
复制标题
实验性糖尿病肾病中基于细胞的干预措施的系统评价与荟萃分析。
DOI：
10.1002/sctm.19-0419
复制
发表时间：
2021-09
影响因子：
6
通讯作者：
Murad MH
中科院分区：
文献类型：
--
作者：
Hickson LJ;Abedalqader T;Ben-Bernard G;Mondy JM;Bian X;Conley SM;Zhu X;Herrmann SM;Kukla A;Lorenz EC;Kim SR;Thorsteinsdottir B;Lerman LO;Murad MH
再生性细胞疗法是目前无法治愈的糖尿病肾病（DKD）一种很有前景的治疗选择。为临床转化做准备，本系统评价与荟萃分析总结了细胞干预对DKD动物模型的疗效，以及影响治疗效果的相关因素。我们检索了电子数据库中1998年1月至2019年5月期间以糖尿病动物肾脏指标为终点、应用细胞疗法的原创性研究。对肾脏相关指标的加权均数差或标准化均数差进行估算，并采用随机效应模型进行汇总分析。通过亚组分析检验影响治疗效果的相关因素（肌酐、尿素、尿蛋白、纤维化和炎症）。40项研究（992只糖尿病啮齿动物）中，所采用的疗法包括间充质干细胞/基质细胞（MSC，占61%）、脐带/羊水细胞（UC/AF，占15%）、非间充质干细胞（占15%）以及细胞衍生产品（占13%）。细胞组织来源包括骨髓（BM，占65%）、脐带/羊水（占15%）、脂肪（占9%）及其他（占11%）。细胞疗法显著改善了肾功能，同时降低了损伤标志物水平（蛋白尿、组织学指标、纤维化、炎症、细胞凋亡、上皮 - 间充质转化、氧化应激）。预处理、异种移植和疾病源方法均有效。间充质干细胞和脐带/羊水细胞对肾功能的改善作用更显著，而细胞产品对纤维化的改善效果更佳。与脂肪或其他组织来源相比，骨髓和脐带/羊水来源的细胞能更有效地改善肾功能和蛋白尿。细胞剂量、给药频率和给药途径也会带来不同的益处。总之，对糖尿病动物进行细胞干预可改善肾功能并减轻损伤，且治疗相关因素会影响这些效果。这些研究结果有助于通过选择性使用细胞/产品、组织来源和给药剂量，开发出最佳修复策略，从而使这种新型疗法成功应用于人类糖尿病肾病的治疗。
《细胞疗法促进糖尿病肾病修复：一项系统评价与荟萃分析》
Regenerative, cell‐based therapy is a promising treatment option for diabetic kidney disease (DKD), which has no cure. To prepare for clinical translation, this systematic review and meta‐analysis summarized the effect of cell‐based interventions in DKD animal models and treatment‐related factors modifying outcomes. Electronic databases were searched for original investigations applying cell‐based therapy in diabetic animals with kidney endpoints (January 1998‐May 2019). Weighted or standardized mean differences were estimated for kidney outcomes and pooled using random‐effects models. Subgroup analyses tested treatment‐related factor effects for outcomes (creatinine, urea, urine protein, fibrosis, and inflammation). In 40 studies (992 diabetic rodents), therapy included mesenchymal stem/stromal cells (MSC; 61%), umbilical cord/amniotic fluid cells (UC/AF; 15%), non‐MSC (15%), and cell‐derived products (13%). Tissue sources included bone marrow (BM; 65%), UC/AF (15%), adipose (9%), and others (11%). Cell‐based therapy significantly improved kidney function while reducing injury markers (proteinuria, histology, fibrosis, inflammation, apoptosis, epithelial‐mesenchymal‐transition, oxidative stress). Preconditioning, xenotransplantation, and disease‐source approaches were effective. MSC and UC/AF cells had greater effect on kidney function while cell products improved fibrosis. BM and UC/AF tissue sources more effectively improved kidney function and proteinuria vs adipose or other tissues. Cell dose, frequency, and administration route also imparted different benefits. In conclusion, cell‐based interventions in diabetic animals improved kidney function and reduced injury with treatment‐related factors modifying these effects. These findings may aid in development of optimal repair strategies through selective use of cells/products, tissue sources, and dose administrations to allow for successful adaptation of this novel therapeutic in human DKD. Cell‐based therapies improve diabetic kidney repair: a systematic review and meta‐analysis.
登录
查看更多内容
影响因子：
3
作者：
Hamza AH;Al-Bishri WM;Damiati LA;Ahmed HH
通讯作者：
Ahmed HH
影响因子：
6
作者：
Ebrahim, Nesrine;Ahmed, Inas A.;Sabry, Dina
通讯作者：
Sabry, Dina
影响因子：
1.9
作者：
Duval, S;Tweedie, R
通讯作者：
Tweedie, R
影响因子：
5.2
作者：
Eirin, Alfonso;Zhu, Xiang-Yang;Krier, James D.;Tang, Hui;Jordan, Kyra L.;Grande, Joseph P.;Lerman, Amir;Textor, Stephen C.;Lerman, Lilach O.
通讯作者：
Lerman, Lilach O.
血管紧张素受体阻滞剂对早期糖尿病肾病足细胞表型改变的影响
影响因子：
3.1
作者：
Dai, Hou-Yong;Zheng, Min;Liu, Bi-Cheng
通讯作者：
Liu, Bi-Cheng